No. Current regulations (21 CFR Parts 210, 211 for pharmaceuticals and Parts 600, 610 for biological products)
provide a degree of flexibility to allow the FDA to shift emphasis to a science-based, risk management approach.
However, the agency is considering the possibility of revising these regulations (21 CFR 600-610) in the future.
